Cargando…

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control

Detalles Bibliográficos
Autores principales:	Jia, Guanghong, Aroor, Annayya R., Sowers, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2016
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878428/ https://www.ncbi.nlm.nih.gov/pubmed/27222394 http://dx.doi.org/10.2337/dbi16-0014

Ejemplares similares

Mineralocorticoid Receptors: An Appealing Target to Treat Coronary Microvascular Dysfunction in Diabetes
por: Bender, Shawn B., et al.
Publicado: (2015)

Uncovering a Mineralocorticoid Receptor–Dependent Adipose–Vascular Axis: Implications for Vascular Dysfunction in Obesity?
por: Jia, Guanghong, et al.
Publicado: (2016)

The Role of Tissue Renin-Angiotensin-Aldosterone System in the Development of Endothelial Dysfunction and Arterial Stiffness
por: Aroor, Annayya R., et al.
Publicado: (2013)

Vascular stiffness in insulin resistance and obesity
por: Jia, Guanghong, et al.
Publicado: (2015)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

New Thoughts in an Old Player: Role of Nitrite in the Treatment of Ischemic Revascularization
por: Jia, Guanghong, et al.
Publicado: (2014)

Interaction of Islet α-Cell and β-Cell in the Regulation of Glucose Homeostasis in HI/HA Syndrome Patients With the GDH(H454Y) Mutation
por: Jia, Guanghong, et al.
Publicado: (2014)

Caveolin-1 in Cardiovascular Disease: A Double-Edged Sword
por: Jia, Guanghong, et al.
Publicado: (2015)

Targeting CITED2 for Angiogenesis in Obesity and Insulin Resistance
por: Jia, Guanghong, et al.
Publicado: (2016)

Increased Fibro-Adipogenic Progenitors and Intramyocellular Lipid Accumulation in Obesity-Related Skeletal Muscle Dysfunction
por: Jia, Guanghong, et al.
Publicado: (2019)

Cardiac Insulin Resistance and MicroRNA Modulators
por: Pulakat, Lakshmi, et al.
Publicado: (2012)

Clinical relevance of dual agonist of glucagon and glucagon‐like peptide‐1 receptors to achieve functional restoration of first‐ and second‐phase insulin secretion
por: Kimura, Tomohiko, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

SAT-LB011 Role of Endothelium Epithelial Sodium Channel in Arterial Stiffness
por: Jia, Guanghong, et al.
Publicado: (2019)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
por: Araki, Eiichi, et al.
Publicado: (2022)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Endothelium-Derived Hyperpolarizing Factors: A Potential Therapeutic Target for Vascular Dysfunction in Obesity and Insulin Resistance
por: Jia, Guanghong, et al.
Publicado: (2016)

Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients
por: Kim, Min Kyung, et al.
Publicado: (2021)

Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
por: Kalra, Sanjay
Publicado: (2014)

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023)

SAT-LB97 MiRNA-99a and mTOR2 Mediate Enhanced Endothelial Mineralocorticoid Receptor Signaling-Induced Activation of Sodium Channel and Endothelium Stiffness
por: Jia, Guanghong, et al.
Publicado: (2020)

Interaction of Adipogenesis and Angiogenesis in Dietary-Induced Obesity
por: Jia, Guanghong, et al.
Publicado: (2015)

The VASP Road to NAFLD: A Macrophage Detour
por: Lastra, Guido, et al.
Publicado: (2015)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis
por: Yamane, Shunsuke, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation
por: Cahill, Katherine N., et al.
Publicado: (2022)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
por: Butler, P. C., et al.
Publicado: (2009)

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
por: Behme, Margaret T, et al.
Publicado: (2003)

Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet
por: Martinez-Lemus, Luis A., et al.
Publicado: (2017)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Role of Perivascular Adipose Tissue on Vascular Reactive Oxygen Species in Type 2 Diabetes: A Give-and-Take Relationship
por: Padilla, Jaume, et al.
Publicado: (2015)

Novel Insights Into the Regulation of Postprandial Lipemia by Glucagon-Like Peptides: Significance for Diabetes
por: Watts, Gerald F., et al.
Publicado: (2013)

Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?
por: Daniels, Derek, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 receptor agonists, weight loss, and gastric emptying: have I gut news for you
por: Jalleh, Ryan J., et al.
Publicado: (2022)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Serotonin receptor HTR4 as a counter actor of lipid-induced increases of serum glucagon-like peptide-1 levels
por: Breit, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7shggvdgajmcukslmklfqn39kd